Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet (London, England)
Gershenson, David M DM; Miller, Austin A; Brady, William E WE; Paul, James J; Carty, Karen K; Rodgers, William W; Millan, David D; Coleman, Robert L RL; Moore, Kathleen N KN; Banerjee, Susana S; Connolly, Kate K; Secord, Angeles Alvarez AA; O'Malley, David M DM; Dorigo, Oliver O; Gaillard, Stephanie S; Gabra, Hani H; Slomovitz, Brian B; Hanjani, Parviz P; Farley, John J; Churchman, Michael M; Ewing, Ailith A; Hollis, Robert L RL; Herrington, C Simon CS; Huang, Helen Q HQ; Wenzel, Lari L; Gourley, Charlie C
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
Lancet (London, England)
Gershenson, David M DM; Miller, Austin A; Brady, William E WE; Paul, James J; Carty, Karen K; Rodgers, William W; Millan, David D; Coleman, Robert L RL; Moore, Kathleen N KN; Banerjee, Susana S; Connolly, Kate K; Secord, Angeles Alvarez AA; O'Malley, David M DM; Dorigo, Oliver O; Gaillard, Stephanie S; Gabra, Hani H; Slomovitz, Brian B; Hanjani, Parviz P; Farley, John J; Churchman, Michael M; Ewing, Ailith A; Hollis, Robert L RL; Herrington, C Simon CS; Huang, Helen Q HQ; Wenzel, Lari L; Gourley, Charlie C
CRISPR/Cas9 uPAR Gene Knockout Results in Tumor Growth Inhibition, EGFR Downregulation and Induction of Stemness Markers in Melanoma and Colon Carcinoma Cell Lines.
Frontiers In Oncology
Biagioni, Alessio A; Chillà, Anastasia A; Del Rosso, Mario M; Fibbi, Gabriella G; Scavone, Francesca F; Andreucci, Elena E; Peppicelli, Silvia S; Bianchini, Francesca F; Calorini, Lido L; Li Santi, Anna A; Ragno, Pia P; Margheri, Francesca F; Laurenzana, Anna A
Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy.
Cancers
Zocchi, Maria Raffaella MR; Tosetti, Francesca F; Benelli, Roberto R; Poggi, Alessandro A
Zappavigna, Silvia S; Cossu, Alessia Maria AM; Grimaldi, Anna A; Bocchetti, Marco M; Ferraro, Giuseppe Andrea GA; Nicoletti, Giovanni Francesco GF; Filosa, Rosanna R; Caraglia, Michele M
uPAR Knockout Results in a Deep Glycolytic and OXPHOS Reprogramming in Melanoma and Colon Carcinoma Cell Lines.
Cells
Biagioni, Alessio A; Laurenzana, Anna A; Chillà, Anastasia A; Del Rosso, Mario M; Andreucci, Elena E; Poteti, Martina M; Bani, Daniele D; Guasti, Daniele D; Fibbi, Gabriella G; Margheri, Francesca F
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy.
Nature Communications
Talebi, Ali A; Dehairs, Jonas J; Rambow, Florian F; Rogiers, Aljosja A; Nittner, David D; Derua, Rita R; Vanderhoydonc, Frank F; Duarte, Joao A G JAG; Bosisio, Francesca F; Van den Eynde, Kathleen K; Nys, Kris K; Pérez, Mónica Vara MV; Agostinis, Patrizia P; Waelkens, Etienne E; Van den Oord, Joost J; Fendt, Sarah-Maria SM; Marine, Jean-Christophe JC; Swinnen, Johannes V JV
Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.
Journal Of Experimental & Clinical Cancer Research : Cr
Ragone, Concetta C; Minopoli, Michele M; Ingangi, Vincenzo V; Botti, Giovanni G; Fratangelo, Federica F; Pessi, Antonello A; Stoppelli, Maria Patrizia MP; Ascierto, Paolo Antonio PA; Ciliberto, Gennaro G; Motti, Maria Letizia ML; Carriero, Maria Vincenza MV
ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells.
Autophagy
Piao, Shengfu S; Ojha, Rani R; Rebecca, Vito W VW; Samanta, Arabinda A; Ma, Xiao-Hong XH; Mcafee, Quentin Q; Nicastri, Michael C MC; Buckley, Meghan M; Brown, Eric E; Winkler, Jeffrey D JD; Gimotty, Phyllis A PA; Amaravadi, Ravi K RK
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype.
Embo Molecular Medicine
Hager, Martin H MH; Morley, Samantha S; Bielenberg, Diane R DR; Gao, Sizhen S; Morello, Matteo M; Holcomb, Ilona N IN; Liu, Wennuan W; Mouneimne, Ghassan G; Demichelis, Francesca F; Kim, Jayoung J; Solomon, Keith R KR; Adam, Rosalyn M RM; Isaacs, William B WB; Higgs, Henry N HN; Vessella, Robert L RL; Di Vizio, Dolores D; Freeman, Michael R MR
microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C.
The Embo Journal
Penna, Elisa E; Orso, Francesca F; Cimino, Daniela D; Tenaglia, Enrico E; Lembo, Antonio A; Quaglino, Elena E; Poliseno, Laura L; Haimovic, Adele A; Osella-Abate, Simona S; De Pittà, Cristiano C; Pinatel, Eva E; Stadler, Michael B MB; Provero, Paolo P; Bernengo, Maria Grazia MG; Osman, Iman I; Taverna, Daniela D
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases.
Molecular Cancer Research : Mcr
Xu, Lei L; Shen, Steven S SS; Hoshida, Yujin Y; Subramanian, Aravind A; Ross, Ken K; Brunet, Jean-Philippe JP; Wagner, Stephan N SN; Ramaswamy, Sridhar S; Mesirov, Jill P JP; Hynes, Richard O RO
Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.
British Journal Of Cancer
Dev, I K IK; Dornsife, R E RE; Hopper, T M TM; Onori, J A JA; Miller, C G CG; Harrington, L E LE; Dold, K M KM; Mullin, R J RJ; Johnson, J H JH; Crosby, R M RM; Truesdale, A T AT; Epperly, A H AH; Hinkle, K W KW; Cheung, M M; Stafford, J A JA; Luttrell, D K DK; Kumar, R R